NRL-ETF Director of Education & Research
National Right to Life
On February 23rd, a group of doctors calling themselves the Mifeprex REMS Study Group (mifeprex is the U.S. trade name of mifepristone) published an article in the New England Journal of Medicine titled “Sixteen Years of Overregulation: Time to Unburden.” They called for an end to remaining special restrictions on the drug, asking that it be made available by prescription at retail pharmacies.
As we discuss later in this article, this is not a call of America’s family physicians or pediatricians or even the majority of the country’s Ob-Gyns. This is a publicity ploy of some of America’s top abortion academic activists, trying to pressure the FDA to go even farther than they felt comfortable going just eleven months ago.
Currently, even with the new FDA label, mifepristone is only supposed to be dispensed in clinics, private doctors’ offices, or hospitals by or under the supervision of a “certified healthcare provider” (it used to specify “physician’).
National Right to Life article continues